Lead Product(s) : Radgocitabine,Venetoclax
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Delta-Fly Updates on DFP-10917, Venetoclax Combination Development Progress
Details : DFP-10917 (radgocitabine) is a DNA polymerase inhibitor small molecule, being evaluated in combination with venetoclax for the treatment of R/R acute myeloid leukemia.
Product Name : DFP-10917
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
February 28, 2025
Lead Product(s) : Radgocitabine,Venetoclax
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Radgocitabine,Venetoclax
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Delta-Fly Pharma Submits Phase I/II Protocol of DFP-10917 and Venetoclax for AML to FDA
Details : DFP-10917 (radgocitabine) is a DNA polymerase inhibitor small molecule drug candidate which is being evaluated in combination with venetoclax for the treatment of acute myeloid leukemia.
Product Name : DFP-10917
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
November 03, 2024
Lead Product(s) : Radgocitabine,Venetoclax
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Radgocitabine,Venetoclax
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Delta-Fly Shows Initial Phase 1/2 Data for AML Combo Therapy
Details : DFP-10917 (radgocitabine) is a DNA polymerase inhibitor small molecule drug candidate which is being evaluated in combination with venetoclax for the treatment of acute myeloid leukemia.
Product Name : DFP-10917
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
October 28, 2024
Lead Product(s) : Radgocitabine,Venetoclax
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Radgocitabine,Venetoclax
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Delta-Fly Initiates Enrollment for Ph I/II Combo-Study of DFP-10917 and Venetoclax in AML
Details : DFP-10917 (radgocitabine) is a DNA polymerase inhibitor small molecule drug candidate which is being evaluated in combination with venetoclax for the treatment of acute myeloid leukemia.
Product Name : DFP-10917
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
October 09, 2024
Lead Product(s) : Radgocitabine,Venetoclax
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Radgocitabine,Venetoclax
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Delta-Fly Pharma Authorized to Conduct Phase I/II of DFP-10917 Combined with Venetoclax
Details : DFP-10917 (radgocitabine) is a DNA polymerase inhibitor small molecule drug candidate which is being evaluated in combination with venetoclax for the treatment of acute myeloid leukemia.
Product Name : DFP-10917
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
August 04, 2024
Lead Product(s) : Radgocitabine,Venetoclax
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Radgocitabine
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Nippon Shinyaku
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DFP-10917 (radgocitabine) is a nucleoside analog delivered as a low-dose continuous infusion for the treatment of relapsed/refractory acute myeloid leukemia.
Product Name : DFP-10917
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
May 15, 2023
Lead Product(s) : Radgocitabine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Nippon Shinyaku
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Radgocitabine
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DFP-10917 (4-amino-1-(2-cyano-deoxy-β-D-arabinofuranosyl)-2(1H)-pyrimidinone monohydrochloride), deoxycytidine nucleoside analogue, has unique mechanism of action resulting in leukemic cell death when administered for prolonged periods at low doses.
Product Name : DFP-10917
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
July 12, 2022
Lead Product(s) : Radgocitabine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable